Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
GENE:
MCL1 (Myeloid cell leukemia 1)
i
Other names:
MCL1, MCL1 Apoptosis Regulator BCL2 Family Member, Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1, Myeloid Cell Leukemia Sequence 1 (BCL2-Related), MCL1 BCL2 Family Apoptosis Regulator, Bcl-2-Related Protein EAT/Mcl1, Myeloid Cell Leukemia 1, Bcl-2-Like Protein 3, Bcl2-L-3, Mcl1/EAT, BCL2L3, BCL2 Family Apoptosis Regulator, Myeloid Cell Leukemia ES, MCL1-ES, MCL1L, MCL1S, Mcl-1, EAT, TM
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4170
Associations
(36)
News
Trials
VERI cancer hierarchy
Reset Filters
MCL1 underexpression
Small Cell Lung Cancer
MCL1 underexpression
Small Cell Lung Cancer
cisplatin
Sensitive: C3 – Early Trials
cisplatin
Sensitive
:
C3
cisplatin
Sensitive: C3 – Early Trials
cisplatin
Sensitive
:
C3
BCL2/MCL1 ratio elevation
Acute Myelogenous Leukemia
BCL2/MCL1 ratio elevation
Acute Myelogenous Leukemia
venetoclax + RG7388
Sensitive: C3 – Early Trials
venetoclax + RG7388
Sensitive
:
C3
venetoclax + RG7388
Sensitive: C3 – Early Trials
venetoclax + RG7388
Sensitive
:
C3
PTPN11 mutations + MCL1 overexpression
Acute Myelogenous Leukemia
PTPN11 mutations + MCL1 overexpression
Acute Myelogenous Leukemia
RG7388
Sensitive: C3 – Early Trials
RG7388
Sensitive
:
C3
RG7388
Sensitive: C3 – Early Trials
RG7388
Sensitive
:
C3
MCL1 amplification
Endometrial Cancer
MCL1 amplification
Endometrial Cancer
CYC065
Sensitive: C3 – Early Trials
CYC065
Sensitive
:
C3
CYC065
Sensitive: C3 – Early Trials
CYC065
Sensitive
:
C3
MCL1 overexpression
Chronic Lymphocytic Leukemia
MCL1 overexpression
Chronic Lymphocytic Leukemia
venetoclax
Resistant: C3 – Early Trials
venetoclax
Resistant
:
C3
venetoclax
Resistant: C3 – Early Trials
venetoclax
Resistant
:
C3
BCL2/MCL1 ratio elevation
Multiple Myeloma
BCL2/MCL1 ratio elevation
Multiple Myeloma
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
MCL1 amplification
Triple Negative Breast Cancer
MCL1 amplification
Triple Negative Breast Cancer
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
KDR amplification + FLT4 amplification + MCL1 amplification + TP53 R213 + TP53 H179Y + ARID1A Q2128
Sarcoma
KDR amplification + FLT4 amplification + MCL1 amplification + TP53 R213 + TP53 H179Y + ARID1A Q2128
Sarcoma
sorafenib
Resistant: C4 – Case Studies
sorafenib
Resistant
:
C4
sorafenib
Resistant: C4 – Case Studies
sorafenib
Resistant
:
C4
MCL1 overexpression
Multiple Myeloma
MCL1 overexpression
Multiple Myeloma
venetoclax
Resistant: D – Preclinical
venetoclax
Resistant
:
D
venetoclax
Resistant: D – Preclinical
venetoclax
Resistant
:
D
BCL2 overexpression + MCL1 overexpression
Diffuse Large B Cell Lymphoma
BCL2 overexpression + MCL1 overexpression
Diffuse Large B Cell Lymphoma
ibrutinib + APG-2575
Sensitive: D – Preclinical
ibrutinib + APG-2575
Sensitive
:
D
ibrutinib + APG-2575
Sensitive: D – Preclinical
ibrutinib + APG-2575
Sensitive
:
D
BCL2 overexpression + MCL1 expression
Diffuse Large B Cell Lymphoma
BCL2 overexpression + MCL1 expression
Diffuse Large B Cell Lymphoma
APG-115 + APG-2575
Sensitive: D – Preclinical
APG-115 + APG-2575
Sensitive
:
D
APG-115 + APG-2575
Sensitive: D – Preclinical
APG-115 + APG-2575
Sensitive
:
D
MCL1 expression
Multiple Myeloma
MCL1 expression
Multiple Myeloma
APG-3526
Sensitive: D – Preclinical
APG-3526
Sensitive
:
D
APG-3526
Sensitive: D – Preclinical
APG-3526
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.